2,321 reports of this reaction
2.6% of all RANITIDINE HYDROCHLORIDE reports
#9 most reported adverse reaction
GASTRIC CANCER is the #9 most commonly reported adverse reaction for RANITIDINE HYDROCHLORIDE, manufactured by WinCo Foods, LLC. There are 2,321 FDA adverse event reports linking RANITIDINE HYDROCHLORIDE to GASTRIC CANCER. This represents approximately 2.6% of all 90,318 adverse event reports for this drug.
RANITIDINE HYDROCHLORIDE has an overall safety score of 95 out of 100. Patients taking RANITIDINE HYDROCHLORIDE who experience gastric cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTRIC CANCER is a less commonly reported adverse event for RANITIDINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to gastric cancer, the following adverse reactions have been reported for RANITIDINE HYDROCHLORIDE:
The following drugs have also been linked to gastric cancer in FDA adverse event reports:
GASTRIC CANCER has been reported as an adverse event in 2,321 FDA reports for RANITIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTRIC CANCER accounts for approximately 2.6% of all adverse event reports for RANITIDINE HYDROCHLORIDE, making it a notable side effect.
If you experience gastric cancer while taking RANITIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.